Back to Browse Journals » Journal of Pain Research » Volume 3

Milnacipran for the management of fibromyalgia syndrome

Authors Michelle J Ormseth, Anne E Eyler, Cara L Hammonds, et al

Published Date March 2010 Volume 2010:3 Pages 15—24

DOI http://dx.doi.org/10.2147/JPR.S7883

Published 1 March 2010

Michelle J Ormseth, Anne E Eyler, Cara L Hammonds, Chad S Boomershine

Division of Rheumatology and Immunology, Vanderbilt University, Nashville, TN, USA

Abstract: Fibromyalgia syndrome (FMS) is a widespread pain condition associated with fatigue, cognitive dysfunction, sleep disturbance, depression, anxiety, and stiffness. Milnacipran is one of three medications currently approved by the Food and Drug Administration in the United States for the management of adult FMS patients. This review is the second in a three-part series reviewing each of the approved FMS drugs and serves as a primer on the use of milnacipran in FMS treatment including information on pharmacology, pharmacokinetics, safety and tolerability. Milnacipran is a mixed serotonin and norepinephrine reuptake inhibitor thought to improve FMS symptoms by increasing neurotransmitter levels in descending central nervous system inhibitory pathways. Milnacipran has proven efficacy in managing global FMS symptoms and pain as well as improving symptoms of fatigue and cognitive dysfunction without affecting sleep. Due to its antidepressant activity, milnacipran can also be beneficial to FMS patients with coexisting depression. However, side effects can limit milnacipran tolerability in FMS patients due to its association with headache, nausea, tachycardia, hyper- and hypotension, and increased risk for bleeding and suicidality in at-risk patients. Tolerability can be maximized by starting at low dose and slowly up-titrating if needed. As with all medications used in FMS management, milnacipran works best when used as part of an individualized treatment regimen that includes resistance and aerobic exercise, patient education and behavioral therapies.
Keywords: fibromyalgia, milnacipran, treatment

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Duloxetine in the management of diabetic peripheral neuropathic pain

Ormseth MJ, Scholz BA, Boomershine CS

Patient Preference and Adherence 2011, 5:343-356

Published Date: 19 July 2011

Pregabalin for the management of fibromyalgia syndrome

Chad S Boomershine

Journal of Pain Research 2010, 3:81-88

Published Date: 22 June 2010

Duloxetine for the management of fibromyalgia syndrome

Beth A Scholz, Cara L Hammonds, Chad S Boomershine

Journal of Pain Research 2009, 2:99-108

Published Date: 21 July 2009

Readers of this article also read:

Local delivery of minocycline-loaded PEG-PLA nanoparticles for the enhanced treatment of periodontitis in dogs

Yao WX, Xu PC, Pang ZQ, Zhao JJ, Chai ZL, Li XX, Li H, Jiang ML, Cheng HB, Zhang B, Cheng NN

International Journal of Nanomedicine 2014, 9:3963-3970

Published Date: 18 August 2014

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Novel nano-rough polymers for cartilage tissue engineering

Balasundaram G, Storey DM, Webster TJ

International Journal of Nanomedicine 2014, 9:1845-1853

Published Date: 15 April 2014

Effects of titania nanotubes with or without bovine serum albumin loaded on human gingival fibroblasts

Liu X, Zhou X, Li S, Lai R, Zhou Z, Zhang Y, Zhou L

International Journal of Nanomedicine 2014, 9:1185-1198

Published Date: 6 March 2014

3D conductive nanocomposite scaffold for bone tissue engineering

Shahini A, Yazdimamaghani M, Walker KJ, Eastman MA, Hatami-Marbini H, Smith BJ, Ricci JL, Madihally SV, Vashaee D, Tayebi L

International Journal of Nanomedicine 2014, 9:167-181

Published Date: 24 December 2013

Muscular effects of statins in the elderly female: a review

Bhardwaj S, Selvarajah S, Schneider EB

Clinical Interventions in Aging 2013, 8:47-59

Published Date: 18 January 2013

Application of magnetically induced hyperthermia in the model protozoan Crithidia fasciculata as a potential therapy against parasitic infections

Grazú V, Silber AM, Moros M, Asín L, Torres TE, Marquina C, Ibarra MR, Goya GF

International Journal of Nanomedicine 2012, 7:5351-5360

Published Date: 8 October 2012

Giant cell arteritis: the importance of immediate and appropriate diagnosis and treatment for better prognosis

Pacella F, Mazzeo F, Giorgi D, Cerutti F, Impallara D, Cuozzo G, Soldini M, Pacella E

Clinical Ophthalmology 2012, 6:909-913

Published Date: 13 June 2012

Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells

Kanmogne GD, Singh S, Roy U, Liu X, McMillan J, Gorantla S, Balkundi S, Smith N, Alnouti Y, Gautam N, Zhou Y, Poluektova L, Kabanov A, Bronich T, Gendelman HE

International Journal of Nanomedicine 2012, 7:2373-2388

Published Date: 8 May 2012

Investigational pharmacology for low back pain

Avinash K Bhandary, Gary P Chimes, Gerard A Malanga

Journal of Pain Research 2010, 3:169-181

Published Date: 6 September 2010